 Alessandra Maleddu
Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Stromal Tumors | 10 | 2011 | 46 | 1.280 |
Why?
| | Sarcoma, Alveolar Soft Part | 1 | 2023 | 7 | 0.840 |
Why?
| | Antineoplastic Agents | 6 | 2023 | 2042 | 0.730 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 6 | 2011 | 45 | 0.580 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2011 | 68 | 0.560 |
Why?
| | Positron-Emission Tomography | 7 | 2011 | 283 | 0.540 |
Why?
| | Pyrroles | 1 | 2009 | 190 | 0.290 |
Why?
| | Liver Neoplasms | 3 | 2009 | 637 | 0.290 |
Why?
| | Protein Kinase Inhibitors | 3 | 2009 | 880 | 0.270 |
Why?
| | Carcinoma, Renal Cell | 1 | 2009 | 180 | 0.270 |
Why?
| | Indoles | 1 | 2009 | 372 | 0.260 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2009 | 431 | 0.250 |
Why?
| | Kidney Neoplasms | 1 | 2009 | 350 | 0.230 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 749 | 0.230 |
Why?
| | Colorectal Neoplasms | 4 | 2011 | 751 | 0.190 |
Why?
| | Quinazolines | 1 | 2023 | 243 | 0.190 |
Why?
| | Osteosarcoma | 1 | 2021 | 72 | 0.180 |
Why?
| | Sarcoma, Ewing | 1 | 2021 | 89 | 0.170 |
Why?
| | Gene Expression Profiling | 4 | 2011 | 1689 | 0.170 |
Why?
| | Sarcoma | 1 | 2021 | 177 | 0.160 |
Why?
| | Bone Neoplasms | 1 | 2021 | 231 | 0.160 |
Why?
| | Radiopharmaceuticals | 2 | 2008 | 166 | 0.140 |
Why?
| | ErbB Receptors | 2 | 2011 | 603 | 0.130 |
Why?
| | Biomarkers, Tumor | 3 | 2011 | 1179 | 0.130 |
Why?
| | DNA Mutational Analysis | 3 | 2011 | 385 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2011 | 1349 | 0.110 |
Why?
| | Neoplasms | 4 | 2009 | 2463 | 0.110 |
Why?
| | Carbon Radioisotopes | 2 | 2009 | 35 | 0.100 |
Why?
| | Interstitial Cells of Cajal | 1 | 2011 | 4 | 0.100 |
Why?
| | Stem Cell Factor | 1 | 2011 | 15 | 0.100 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2011 | 29 | 0.090 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2009 | 127 | 0.090 |
Why?
| | Stomach Neoplasms | 2 | 2009 | 98 | 0.090 |
Why?
| | Humans | 21 | 2023 | 128495 | 0.090 |
Why?
| | Mutation | 3 | 2010 | 3696 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2009 | 757 | 0.080 |
Why?
| | Receptor, IGF Type 1 | 1 | 2009 | 65 | 0.080 |
Why?
| | Medical Oncology | 2 | 2008 | 272 | 0.080 |
Why?
| | Gene Amplification | 1 | 2009 | 104 | 0.080 |
Why?
| | Adrenalectomy | 1 | 2009 | 66 | 0.080 |
Why?
| | Nuclear Medicine | 1 | 2008 | 7 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2011 | 2679 | 0.080 |
Why?
| | Diagnostic Imaging | 2 | 2008 | 332 | 0.080 |
Why?
| | Molecular Probes | 1 | 2008 | 37 | 0.080 |
Why?
| | Esophagitis | 1 | 2009 | 67 | 0.080 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2009 | 91 | 0.080 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2009 | 84 | 0.070 |
Why?
| | Treatment Failure | 1 | 2009 | 338 | 0.070 |
Why?
| | Antibodies, Monoclonal | 3 | 2011 | 1357 | 0.070 |
Why?
| | Nephrectomy | 1 | 2009 | 158 | 0.070 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2009 | 283 | 0.070 |
Why?
| | Fluorouracil | 1 | 2009 | 198 | 0.070 |
Why?
| | Technology Assessment, Biomedical | 1 | 2007 | 29 | 0.070 |
Why?
| | Pancreaticoduodenectomy | 1 | 2009 | 158 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2009 | 163 | 0.070 |
Why?
| | Esophagoscopy | 1 | 2009 | 195 | 0.070 |
Why?
| | Angiogenesis Inhibitors | 1 | 2009 | 215 | 0.070 |
Why?
| | Piperazines | 1 | 2009 | 333 | 0.070 |
Why?
| | Treatment Outcome | 6 | 2010 | 10162 | 0.060 |
Why?
| | Needs Assessment | 1 | 2008 | 356 | 0.060 |
Why?
| | Neoplasm Proteins | 1 | 2008 | 420 | 0.060 |
Why?
| | Prognosis | 2 | 2011 | 3780 | 0.060 |
Why?
| | Pyrimidines | 1 | 2009 | 449 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2010 | 2064 | 0.060 |
Why?
| | Aged | 8 | 2011 | 21974 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2011 | 958 | 0.060 |
Why?
| | Aged, 80 and over | 6 | 2011 | 7057 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 1938 | 0.050 |
Why?
| | Patient Care Team | 1 | 2008 | 598 | 0.050 |
Why?
| | Decision Making | 1 | 2010 | 847 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2008 | 894 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 878 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2011 | 1668 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 4 | 2011 | 2517 | 0.040 |
Why?
| | Middle Aged | 8 | 2011 | 30921 | 0.040 |
Why?
| | Time Factors | 1 | 2009 | 6505 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 941 | 0.040 |
Why?
| | Female | 9 | 2011 | 68266 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2011 | 2329 | 0.040 |
Why?
| | Follow-Up Studies | 3 | 2011 | 4874 | 0.030 |
Why?
| | Adult | 7 | 2011 | 35299 | 0.030 |
Why?
| | Signal Transduction | 1 | 2009 | 4825 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2009 | 1292 | 0.030 |
Why?
| | Gene Expression | 2 | 2010 | 1455 | 0.030 |
Why?
| | Animals | 3 | 2011 | 34647 | 0.030 |
Why?
| | Male | 7 | 2011 | 63043 | 0.020 |
Why?
| | Disease Progression | 2 | 2009 | 2604 | 0.020 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2010 | 41 | 0.020 |
Why?
| | Genes, ras | 1 | 2010 | 97 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2010 | 120 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 61 | 0.020 |
Why?
| | Oncogenes | 1 | 2010 | 111 | 0.020 |
Why?
| | Chromosome Aberrations | 1 | 2010 | 149 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2010 | 125 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 205 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2009 | 67 | 0.020 |
Why?
| | Capecitabine | 1 | 2009 | 46 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 19 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 820 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1027 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 87 | 0.020 |
Why?
| | K562 Cells | 1 | 2008 | 82 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 122 | 0.020 |
Why?
| | Italy | 1 | 2008 | 98 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2009 | 187 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2008 | 267 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 159 | 0.020 |
Why?
| | Benzamides | 1 | 2009 | 195 | 0.020 |
Why?
| | Gastrectomy | 1 | 2009 | 99 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 2008 | 142 | 0.020 |
Why?
| | Genome | 1 | 2010 | 277 | 0.020 |
Why?
| | Bevacizumab | 1 | 2008 | 129 | 0.020 |
Why?
| | Methionine | 1 | 2008 | 157 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2009 | 381 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 2009 | 136 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2008 | 190 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 313 | 0.020 |
Why?
| | Choline | 1 | 2008 | 120 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2010 | 392 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 478 | 0.020 |
Why?
| | Blotting, Western | 1 | 2009 | 1170 | 0.020 |
Why?
| | Forecasting | 1 | 2008 | 356 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2010 | 1201 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2009 | 764 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2008 | 325 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2007 | 290 | 0.020 |
Why?
| | Survival Analysis | 1 | 2009 | 1265 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2008 | 812 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 12349 | 0.020 |
Why?
| | Genotype | 1 | 2010 | 1830 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2007 | 327 | 0.010 |
Why?
| | Immunotherapy | 1 | 2008 | 589 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1003 | 0.010 |
Why?
| | Mice | 2 | 2011 | 16620 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2008 | 758 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 20304 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 3178 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2719 | 0.010 |
Why?
| | Rats | 1 | 2008 | 5246 | 0.010 |
Why?
| | Risk Assessment | 1 | 2009 | 3232 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2008 | 3947 | 0.010 |
Why?
| | Risk Factors | 1 | 2011 | 9737 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2011 | 14471 | 0.010 |
Why?
|
|
Maleddu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|